Conference Coverage

DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening

Publish date: August 27, 2022

 

AT ESC CONGRESS 2022

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

AHA statement outlines symptoms of common heart diseases
MDedge Internal Medicine
Does DTC heart drug advertising discourage lifestyle changes?
MDedge Internal Medicine
Cholesterol levels lowering in U.S., but disparities emerge
MDedge Internal Medicine
How much weight does my patient need to lose?
MDedge Internal Medicine
Barcelona beckons for first hybrid ESC Congress
MDedge Internal Medicine
‘Conservative’ USPSTF primary prevention statin guidance finalized
MDedge Internal Medicine
NSAIDs linked to heart failure risk in diabetes
MDedge Internal Medicine
Early menopause linked with increased risk of heart problems
MDedge Internal Medicine
Secondary CV prevention benefit from polypill promises global health benefit
MDedge Internal Medicine
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
MDedge Internal Medicine